Completed PHASE2 INTERVENTIONAL 2-arm NCT04440592

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Sponsor: Tanabe Pharma America, Inc.

Conditions Diffuse Cutaneous Systemic Sclerosis

Interventions MT-7117 Placebo

Updated 29 times since 2020 Last updated: Dec 12, 2025 Started: Feb 5, 2021 Primary completion: Jan 17, 2024 Completion: Feb 14, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Diffuse Cutaneous Systemic Sclerosis, this trial is completed. The trial is conducted by Tanabe Pharma America, Inc. and has accumulated 29 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

29 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Dec 2025 — Jan 2026 [monthly]

Completed PHASE2
Sep 2025 — Dec 2025 [monthly]

Completed PHASE2
Feb 2025 — Sep 2025 [monthly]

Completed PHASE2
Sep 2024 — Feb 2025 [monthly]

Completed PHASE2

▶ Show 24 earlier versions

Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2024 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Feb 2024 — Apr 2024 [monthly]

Active Not Recruiting PHASE2
Jun 2023 — Feb 2024 [monthly]

Active Not Recruiting PHASE2
May 2023 — Jun 2023 [monthly]

Active Not Recruiting PHASE2
Apr 2023 — May 2023 [monthly]

Active Not Recruiting PHASE2
Jan 2023 — Apr 2023 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE2
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE2
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE2
May 2022 — Jun 2022 [monthly]

Recruiting PHASE2
Apr 2022 — May 2022 [monthly]

Recruiting PHASE2
Feb 2022 — Apr 2022 [monthly]

Recruiting PHASE2
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE2
Nov 2021 — Jan 2022 [monthly]

Recruiting PHASE2
Sep 2021 — Nov 2021 [monthly]

Recruiting PHASE2
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE2
Apr 2021 — Jun 2021 [monthly]

Recruiting PHASE2
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2
Sep 2020 — Dec 2020 [monthly]

Not Yet Recruiting PHASE2
Jul 2020 — Sep 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tanabe Pharma America, Inc.

Data source: Tanabe Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Barcelona, Spain , Bialystok, Poland , Boston, United States , Cona, Italy , Edinburgh, United Kingdom , Elblag, Poland , Erlangen, Germany , Frankfurt am Main, Germany and 22 more locations